Sanofi's Genzyme Reports Treatment Effects Maintained Over Five Years in Majority of Patients with Relapsing Remitting MS who Received Genzyme's Lemtrada
October 08, 2015 at 05:00 AM EDT
Sanofi (NYSE: SNY) and its subsidiary Genzyme today announced positive new five-year investigational data from the extension study of ...
